EpiCor Clinical Study on Rapid Immune Modulating Effects
NCT ID: NCT05819424
Last Updated: 2024-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2023-05-16
2023-11-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Immune Modulation by Probiotic Strain
NCT06754228
Study to Assess the Effect of Multistrain Probiotic on the Immune Response to the Influenza Vaccination
NCT06103994
Clinical Evaluation of the Effects of EpiCor on Digestive Comfort
NCT03051399
A Study of a Prebiotic, a Probiotic and a Synbiotic Upon the Gut Microbiota and Immune Response of Healthy Volunteers
NCT01545219
Probiotic, Prebiotic and Synbiotic Effect on Immunity
NCT01084434
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
30 subjects will participate in a placebo-controlled, double-blind, randomized, cross-over design, wherein they will be taking a placebo, or nutraceutical product, each separated by a 1-week washout period to evaluate effects within 3 hours of consumption.
Blood samples will be taken 1 hour after participants arrive, then the dose is administered. Samples are taken 1 hour, 2 hours, and 3 hours following administration.
A series of immune panels will be used to determine the acute impacts on immune surveillance, immune cell activation status, and cytokine profiles. Ex vivo immune challenges will be used to determine the direct impacts on immune cells.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo intervention first and Active intervention one week later
Participants will be consuming a placebo on a clinic day at least one week prior to a clinic day where they will consume the active intervention.
Yeast Fermentate (EpiCor)
Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients.
Placebo: Substance with no therapeutic value to facilitate blinding
Active intervention first and Placebo intervention one week later
Participants will be consuming active intervention on a clinic day at least 1 week prior to a clinic day where they will consume the placebo.
Yeast Fermentate (EpiCor)
Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients.
Placebo: Substance with no therapeutic value to facilitate blinding
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Yeast Fermentate (EpiCor)
Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients.
Placebo: Substance with no therapeutic value to facilitate blinding
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI between 18 and 30 (inclusive)
* Veins easy to see in one or both arms (to allow for multiple blood draws)
* Willing to comply with a 24-h wash-out period for vitamins and nutritional supplements
* Willing to comply with study procedures including: maintaining a consistent diet and lifestyle routine throughout the study; consistent habit of bland breakfasts on days of clinic visits; abstaining from exercising and nutritional supplements on the morning of the study visit; abstaining from use of coffee, tea, and soft drinks for at least one hour prior to a clinic visit; abstaining from music, candy, bum, computer/cell phone use, during clinic visits.
Exclusion Criteria
* Currently in intensive athletic training (such as marathon runners)
* Currently taking antidepressant or tranquilizing medications
* Taking anti-inflammatory medications on a daily basis
* Currently experiencing intense stressful events/life changes that could negatively affect compliance
* Anything that the investigator judges may put the subject at risk or may unduly influence any of the results of the study
* An unusual sleep routine (examples: working nightshift, irregular routine with frequent late nights)
* Unwilling to maintain a constant intake of supplements over the duration of the study
* Anxiety about having blood drawn
* People of childbearing potential: pregnant, nursing, or trying to become pregnant
* Known food allergies related to ingredients in active test product or placebo
Prescription medication will be evaluated on case-by-case basis.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Natural Immune Systems Inc
OTHER
Cargill
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gitte Jensen, PhD
Role: PRINCIPAL_INVESTIGATOR
NIS Labs
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NIS Labs
Klamath Falls, Oregon, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
004-044
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.